Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases

被引:12
作者
Sugiura, Ayumi [1 ]
Joshita, Satoru [1 ]
Yamashita, Yuki [1 ]
Yamazaki, Tomoo [1 ]
Fujimori, Naoyuki [1 ]
Kimura, Takefumi [1 ]
Matsumoto, Akihiro [1 ,2 ]
Wada, Shuichi [3 ]
Mori, Hiromitsu [3 ]
Shibata, Soichiro [3 ]
Yoshizawa, Kaname [4 ]
Morita, Susumu [4 ]
Furuta, Kiyoshi [5 ]
Kamijo, Atsushi [5 ]
Iijima, Akihiro [6 ]
Kako, Satoko [6 ]
Maruyama, Atsushi [7 ]
Kobayashi, Masakazu [8 ]
Komatsu, Michiharu [8 ]
Matsumura, Makiko [9 ]
Miyabayashi, Chiharu [10 ]
Ichijo, Tetsuya [11 ]
Takeuchi, Aki [12 ]
Koike, Yuriko [13 ]
Gibo, Yukio [14 ]
Tsukadaira, Toshihisa [15 ]
Inada, Hiroyuki [16 ]
Nakano, Yoshiyuki [17 ]
Usuda, Seiichi [18 ]
Kiyosawa, Kendo [18 ]
Tanaka, Eiji [19 ]
Umemura, Takeji [1 ,20 ]
机构
[1] Shinshu Univ, Dept Med, Div Gastroenterol & Hepatol, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[2] Shinshu Univ Hosp, Consultat Ctr Hepat Dis, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[3] Japanese Red Cross Soc Nagano Hosp, Dept Gastroenterol, 22-1 Wakasato, Nagano, Nagano 3800928, Japan
[4] Natl Hosp Org, Shinshu Ueda Med Ctr, Dept Gastroenterol, 27-21 Midorigaoka, Ueda, Nagano 3868610, Japan
[5] Natl Hosp Org, Matsumoto Med Ctr, Dept Gastroenterol, 20-30 Muraimachiminami, Matsumoto, Nagano 3998701, Japan
[6] Nagano Prefectural Kiso Hosp, Dept Internal Med, 6613-4 Fukushima, Kiso, Nagano 3978555, Japan
[7] Ina Cent Hosp, Dept Gastroenterol, 1313-1 Koshiroukubo, Ina, Nagano 3968555, Japan
[8] Japanese Red Cross Soc Suwa Hosp, Dept Gastroenterol, 5-11-50 Kogandori, Suwa, Nagano 3928510, Japan
[9] Nagano Chuo Hosp, Dept Gastroenterol, 1570 Tsuruga Nishitsurugamachi, Nagano, Nagano 3800814, Japan
[10] Chikuma Cent Hosp, Dept Gastroenterol, 58 Kuiseshita, Chikuma, Nagano 3870011, Japan
[11] Japanese Red Cross Soc Azumino Hosp, Dept Gastroenterol, 5685 Toyoshina, Azumino, Nagano 3998205, Japan
[12] Aki Naika Clin, 236-1 Nozawa, Saku, Nagano 3850053, Japan
[13] Kawanakajima Clin, 1942-25 Kawanagajima Machi, Nagano, Nagano 3812221, Japan
[14] Gibo Hepatol Clin, 1-34-20 Muraimachiminami, Matsumoto, Nagano 3990036, Japan
[15] Kenwakai Hosp, Dept Gastroenterol, 1936 Kanaenakadaira, Iida, Nagano 3958522, Japan
[16] Kanebako Internal Med Clin, 320-2 Kanebako, Nagano, Nagano 3810007, Japan
[17] Nakano Gastroenterol Clin, 4-13-5 Muraimachiminami, Matsumoto, Nagano 3990036, Japan
[18] Aizawa Hosp, Gastroenterol Ctr, 2-5-1 Honjo, Matsumoto, Nagano 3900814, Japan
[19] Shinshu Univ, Dept Community Med Promot, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[20] Shinshu Univ, Inst Biomed Sci, Dept Life Innovat, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
基金
日本学术振兴会;
关键词
chronic hepatitis C; hepatitis C virus; glecaprevir; pibrentasvir; retreatment; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; LIVER-BIOPSY; GENOTYPE; HCV; FIBROSIS;
D O I
10.3390/biomedicines8040074
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glecaprevir/pibrentasvir (G/P) are direct-acting antivirals (DAAs) that achieve a high sustained virological response (SVR) rate for hepatitis C virus (HCV) infection. We investigated G/P effectiveness for HCV patients based on real-world experience and the clinical features of retreatment cases. HCV patients (n = 182) were compared for clinical features and outcomes between first treatment (n = 159) and retreatment (n = 23) G/P groups. Overall, 77 patients (42.3%) were male, the median age was 68 years, and 86/66/1/4 cases had genotype 1/2/1 + 2/3, respectively. An SVR was achieved in 97.8% (178/182) of cases by intention-to-treat analysis and 99.4% (178/179) of cases by per-protocol analysis. There were no remarkable differences between the first treatment and retreatment groups for male (42.8% vs. 39.1%, p = 0.70), median age (68 vs. 68 years, p = 0.36), prior hepatocellular carcinoma (5.8% vs. 8.7%, p = 0.59), or the fibrosis markers AST-to-platelet ratio index (APRI) (0.5 vs. 0.5, p = 0.80) and fibrosis-4 (FIB-4) index (2.2 vs. 2.6, p = 0.59). The retreatment group had a significantly more frequent history of interferon treatment (12.3% vs. 52.2%, p < 0.01) and the Y93H mutation (25.0% vs. 64.7%, p = 0.02). The number of retreatment patients who had experienced 3, 2, and 1 DAA treatment failures was 1, 3, and 19, respectively, all of whom ultimately achieved an SVR by G/P treatment. In conclusion, G/P was effective and safe for both HCV first treatment and retreatment cases despite the retreatment group having specific resistance mutations for other prior DAAs. As G/P treatment failure has been reported for P32 deletions, clinicians should consider resistance mutations during DAA selection.
引用
收藏
页数:11
相关论文
共 25 条
  • [1] JS']JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2
    Asahina, Yasuhiro
    Izumi, Namiki
    Hiromitsu, Kumada
    Kurosaki, Masayuki
    Koike, Kazuhiko
    Suzuki, Fumitaka
    Takikawa, Hajime
    Tanaka, Atsushi
    Tanaka, Eiji
    Tanaka, Yasuhito
    Tsubouchi, Hirohito
    Hayashi, Norio
    Hiramatsu, Naoki
    Yotsuyanagi, Hiroshi
    [J]. HEPATOLOGY RESEARCH, 2016, 46 (02) : 129 - 165
  • [2] Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
    Castéra, L
    Vergniol, J
    Foucher, J
    Le Bail, B
    Chanteloup, E
    Haaser, M
    Darriet, M
    Couzigou, P
    De Lédinghen, V
    [J]. GASTROENTEROLOGY, 2005, 128 (02) : 343 - 350
  • [3] Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
    D'Ambrosio, Roberta
    Pasulo, Luisa
    Puoti, Massimo
    Vinci, Maria
    Schiavini, Monica
    Lazzaroni, Sergio
    Soria, Alessandro
    Gatti, Federico
    Menzaghi, Barbara
    Aghemo, Alessio
    Capelli, Francesca
    Rumi, Maria Grazia
    Morini, Lorenzo
    Giorgini, Alessia
    Pigozzi, Marie Graciella
    Rossini, Angelo
    Maggiolo, Franco
    Pan, Angelo
    Memoli, Massimo
    Spinelli, Ombretta
    Del Poggio, Paolo
    Saladino, Valeria
    Spinetti, Angiola
    De Bona, Anna
    Capretti, Andrea
    Uberti-Foppa, Caterina
    Bonfanti, Paolo
    Terreni, Natalia
    Menozzi, Fernanda
    Colombo, Alberto Eraldo
    Giglio, Omar
    Centenaro, Riccardo
    Borghi, Marta
    Baiguera, Chiara
    Picciotto, Viviana
    Landonio, Simona
    Gori, Andrea
    Magnani, Carlo
    Noventa, Franco
    Paolucci, Stefania
    Lampertico, Pietro
    Fagiuoli, Stefano
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (03) : 379 - 387
  • [4] Is Genotype 3 of the Hepatitis C Virus the New Villain?
    Goossens, Nicolas
    Negro, Francesco
    [J]. HEPATOLOGY, 2014, 59 (06) : 2403 - 2412
  • [5] Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan
    Kanda, Tatsuo
    Yasui, Shin
    Nakamura, Masato
    Suzuki, Eiichiro
    Arai, Makoto
    Haga, Yuki
    Sasaki, Reina
    Wu, Shuang
    Nakamoto, Shingo
    Imazeki, Fumio
    Yokosuka, Osamu
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2016, 13 (06): : 418 - 423
  • [6] Hepatocellular carcinoma: Recent trends in Japan
    Kiyosawa, K
    Umemura, T
    Ichijo, T
    Matsumoto, A
    Yoshizawa, K
    Gad, A
    Tanaka, E
    [J]. GASTROENTEROLOGY, 2004, 127 (05) : S17 - S26
  • [7] INTERRELATIONSHIP OF BLOOD-TRANSFUSION, NON-A, NON-B HEPATITIS AND HEPATOCELLULAR-CARCINOMA - ANALYSIS BY DETECTION OF ANTIBODY TO HEPATITIS-C VIRUS
    KIYOSAWA, K
    SODEYAMA, T
    TANAKA, E
    GIBO, Y
    YOSHIZAWA, K
    NAKANO, Y
    FURUTA, S
    AKAHANE, Y
    NISHIOKA, K
    PURCELL, RH
    ALTER, HJ
    [J]. HEPATOLOGY, 1990, 12 (04) : 671 - 675
  • [8] NATURAL-HISTORY OF HEPATITIS-C
    KIYOSAWA, K
    TANAKA, E
    SODEYAMA, T
    FURUTA, S
    [J]. INTERVIROLOGY, 1994, 37 (02) : 101 - 107
  • [9] Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
    Kumada, Hiromitsu
    Watanabe, Tsunamasa
    Suzuki, Fumitaka
    Ikeda, Kenji
    Sato, Ken
    Toyoda, Hidenori
    Atsukawa, Masanori
    Ido, Akio
    Takaki, Akinobu
    Enomoto, Nobuyuki
    Kato, Koji
    Alves, Katia
    Burroughs, Margaret
    Redman, Rebecca
    Pugatch, David
    Pilot-Matias, Tami J.
    Krishnan, Preethi
    Oberoi, Rajneet K.
    Xie, Wangang
    Chayama, Kazuaki
    [J]. JOURNAL OF GASTROENTEROLOGY, 2018, 53 (04) : 566 - 575
  • [10] Identification of Hepatitis C Virus NS5A Inhibitors
    Lemm, Julie A.
    O'Boyle, Donald, II
    Liu, Mengping
    Nower, Peter T.
    Colonno, Richard
    Deshpande, Milind S.
    Snyder, Lawrence B.
    Martin, Scott W.
    Laurent, Denis R. St.
    Serrano-Wu, Michael H.
    Romine, Jeffrey L.
    Meanwell, Nicholas A.
    Gao, Min
    [J]. JOURNAL OF VIROLOGY, 2010, 84 (01) : 482 - 491